Overview of Indosin

Property	Description
Active ingredient	Indometacin (Indomethacin)
Form	Capsule, Oral suspension, Suppository, Powder for injection
Pharmacological class	Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose	Anti-inflammatory, Analgesic (Pain Relief), Antipyretic (Fever Reduction)
Origin	Synthetic (Indole-acetic acid derivative)

What Type of Medicine is Indosin?

Indosin is a potent, prescription-only medication whose active component is Indometacin (also known as Indomethacin), classifying it as a Non-steroidal Anti-inflammatory Drug (NSAID). NSAIDs are used primarily to treat pain, inflammation, and fever. The active substance is a synthetic compound structurally defined as an indole-acetic acid derivative. This chemical classification within the NSAID group confirms the drug's essential triple function: it acts as an anti-inflammatory drug, an analgesic (pain reliever), and an antipyretic (fever reducer).

Indometacin's Core Purpose and Function

The core function of Indosin is to manage the symptomatic distress associated with inflammation, acute pain, and fever. Its mechanism is rooted in its ability to inhibit the synthesis of chemical signals called prostaglandins. Indometacin achieves its therapeutic effect by blocking the cyclooxygenase (COX) enzyme system, which is vital for the production of these inflammatory mediators. This mechanism is clinically recognized for its efficacy in reducing systemic and localized swelling. By disrupting this chemical pathway, the medication effectively controls symptomatic swelling and tenderness, assists in lowering body temperature, and helps to reduce bodily discomfort.

Available Forms of Indosin (Composition and Preparations)

Indosin is manufactured as a single-ingredient product in several pharmaceutical preparations to allow for different routes of administration. These forms are particularly notable for their clinical versatility, including the standard oral capsule (immediate-release and extended-release versions), an oral suspension, a suppository for rectal administration, and a powder for injection used for intravenous treatment. The availability of these distinct forms allows for administration to specific patient groups, demonstrating a key differentiating factor in its use compared to many standard over-the-counter NSAIDs.

Regulatory References

What side effects are possible with Indosin?

Possible Side Effects and Safety Information

Indosin (Indomethacin) carries a Boxed Warning from regulatory bodies regarding the risk of serious, potentially fatal Cardiovascular (CV) Thrombotic Events and serious Gastrointestinal (GI) Adverse Events. The CV risk includes myocardial infarction and stroke, which can be fatal, and may increase with the duration of use. The GI risk includes bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time without warning symptoms. The drug is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Other serious adverse reactions include new-onset or worsening hypertension, heart failure and fluid retention, renal toxicity (including acute renal failure and hyperkalemia), and hepatotoxicity. Serious and sometimes fatal skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been reported.

Adverse Reaction Categories

The most common adverse reactions (incidence ge 3%) are related to the central nervous system and gastrointestinal systems, and include headache, dizziness, dyspepsia, and nausea. Other potential adverse effects include various psychiatric disturbances, hematologic toxicity (e.g., anemia), and ocular effects.

Safety Considerations

The drug is contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Use in elderly patients is associated with a greater risk of serious GI and CNS effects. Use during pregnancy is restricted from about 20 weeks and avoided at or after 30 weeks gestation due to the risk of fetal renal dysfunction and premature closure of the fetal ductus arteriosus. To minimize risks, it is advised to use the lowest effective dose for the shortest duration consistent with individual treatment goals.

Overdose and Emergency Response

Overdose and When to Seek Help

Indosin (Indometacin) overdosage requires immediate and urgent medical attention. Treatment is symptomatic and supportive, as there is no specific pharmaceutical antidote documented in official regulatory labeling.

Documented Overdose Manifestations

Official regulatory information describes specific manifestations that may occur in cases of overdosage. These signs affect the gastrointestinal and central nervous systems:

Gastrointestinal (GI) Effects: Nausea, vomiting, epigastric pain, and gastrointestinal bleeding.
Central Nervous System (CNS) Effects: Severe headache, confusion, unusual drowsiness, dizziness, tinnitus (ringing in the ears), and potentially seizures.

Severe Outcomes and Emergency Actions

Overdosage, particularly a potentially life-threatening amount, carries a risk of serious organ damage, including acute renal failure and liver damage (hepatotoxicity).

Regulatory authorities explicitly mandate the following immediate actions:

Seek immediate medical attention or contact a poison control center or emergency room at once if overdosage is suspected.
If the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened, immediately call emergency services.

Specific management steps may include administering activated charcoal or performing gastric lavage, based on the dose ingested and the time elapsed since exposure.

Therapeutic Uses of Indosin

What Indosin Treats: Main Uses and Benefits

Indosin is an anti-inflammatory agent commonly used to help manage symptoms related to inflammatory or irritative states. The medication may be part of symptomatic management for conditions presenting with systemic or localized discomfort, including Moderate to Severe Rheumatoid Arthritis, Ankylosing Spondylitis, and acute, intense attacks of Gouty Arthritis. It is also relevant for easing symptoms of localized soft tissue issues such as Bursitis and Tendinitis, and may assist with general support for fever and generalized physical discomfort.

Key Therapeutic Support

Indosin is commonly applied in clinical settings that involve acute or unstable symptom patterns, such as during flare-ups of chronic joint disease or an acute inflammatory episode. It is commonly used to help with symptom clusters that may become intense or disruptive, including persistent joint swelling, tenderness, and stiffness. This supports general well-being and may assist with maintaining a sense of stability when symptoms are more noticeable during symptomatic periods.

“Symptomatic relief is relevant for easing the overall symptom load, which may help patients cope more steadily with difficult episodes.”

Quick Fact: Symptomatic Support for Inflammatory Pain

Quick Fact: Symptomatic Support for Inflammatory Pain
Symptom Focus: Contributes to easing symptoms related to inflammatory states in soft tissues and joints, particularly when symptoms create noticeable physiological strain.

Regulatory References

NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Indosin?

Eligibility for Indosin (Indometacin) is strictly determined by regulatory rules, which define absolute prohibitions (contraindications) and necessary precautions based on a patient's medical status and age. Indosin is a potent Non-steroidal Anti-inflammatory Drug (NSAID) with specific restrictions tied to cardiovascular, gastrointestinal, and renal risks.

Contraindications and Absolute Restrictions

Indosin must not be used in patients with a known hypersensitivity to the drug, or those who have experienced asthma or allergic reactions after taking aspirin or other NSAIDs. It is absolutely contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery and in pregnant women starting at 30 weeks gestation (third trimester).

Condition and Age-Based Limitations

Population Group	Eligibility Status/Restriction
Advanced Renal/Heart Failure	Avoid use unless benefits clearly outweigh the risk of worsening function.
Active GI Issues	Use with extreme caution in patients with a history of ulcer disease or bleeding.
Children under 14	Safety and efficacy for the oral/rectal forms are not established.
Older Adults (65+)	Use with greater care due to increased risk of adverse reactions; requires closer monitoring.
Lactation	Use is not recommended as Indometacin is excreted in breast milk.

The intravenous form is specifically approved for use only in premature infants for a particular cardiac condition.

What should I know about interactions with other medicines?

Indosin's official interaction profile is defined by two primary regulatory concerns: pharmacodynamic risk and altered drug clearance. The regulatory labeling specifies formal restrictions and exposure modifications for co-administered products.

Official Interaction Restrictions

Co-administration is not generally recommended with analgesic doses of Aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including Ketorolac, due to a documented increase in the risk of severe gastrointestinal adverse events. Co-use with Alcohol may intensify adverse effects and heighten the risk of gastrointestinal blood loss.

Pharmacodynamic and Clearance Effects

Indosin's interaction with Anticoagulants (e.g., Warfarin) and Antiplatelet Agents is documented to enhance the risk of bleeding. The medicine may also diminish the antihypertensive effect of ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-Blockers. Furthermore, co-use with Diuretics can reduce the natriuretic and diuretic effect, and the use of Potassium-Sparing Diuretics increases the risk of hyperkalaemia. The official profile notes that Indosin can cause a decreased elimination, resulting in an increase in plasma concentrations of Lithium, Methotrexate, and Digoxin. Specific cautions exist for the Elderly or Renally Impaired, as co-administration with ACE Inhibitors or ARBs may lead to a further deterioration of renal function.

Mechanism of Action

Molecular Inhibition of the Eicosanoid Synthesis Cascade

The core mechanism of Indometacin involves the non-selective and tight-binding inhibition of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2), which catalyze the conversion of arachidonic acid into various eicosanoids, notably Prostaglandin E2 ( PGE2). This COX blockade prevents the formation of PGE2, a primary signal that promotes inflammatory responses and increases the sensitivity of peripheral nociceptive fibers. The resulting physiological consequence is the reduction of inflammatory signaling and the diminished sensitization of these fibers.

Central and Auxiliary Pathway Modulation

Indometacin engages two distinct mechanistic domains beyond COX inhibition. Centrally, it acts within the hypothalamus to inhibit PGE2 synthesis, which allows the central thermal set point to be modulated toward baseline. Peripherally, the molecule inhibits auxiliary systems such as the Phospholipase A2 ( PLA2) enzyme, which suppresses the upstream release of inflammatory substrates. It also acts as a positive allosteric modulator on the Cannabinoid Receptor 1 ( CB1), enhancing endogenous antinociceptive signaling. This central and auxiliary action collectively contributes to the physiological processes of thermoregulation and nociception.

Dosage and Administration Information

Official Administration Guidelines for Indosin

Indosin, containing Indometacin, is administered via three primary routes: oral (capsule and suspension), rectal (suppository), and intravenous (IV) injection, though the IV route is generally reserved for specific conditions like the closure of the patent ductus arteriosus in neonates.

All oral dosage forms, including the immediate-release (IR) and extended-release (ER) capsules and the oral suspension, are typically taken with food, immediately after a meal, or with antacids.

Dosing Patterns and Frequency

Dosage is determined by the specific condition being addressed and is based on the principle of using the lowest effective dose for the shortest duration.

Indication (High-Level Adult)	Typical Starting Dose (IR Capsule)	Frequency & Adjustment Pattern
Chronic Conditions (e.g., Arthritis)	25 mg	Two to three times per day; may be increased by 25 mg or 50 mg at weekly intervals up to a maximum of 200 mg daily.
Acute Conditions (e.g., Gouty Arthritis)	50 mg	Three times per day; the dose is then rapidly reduced once symptoms are tolerable.

The Extended-Release (ER) 75 mg capsule is typically used once daily, or in two divided doses, up to a maximum of 150 mg per day. The IR capsules and oral suspension, conversely, utilize a divided-dose schedule. The oral suspension must be shaken well before each use. Importantly, ER capsules must not be crushed, broken, or chewed, as this alters the controlled release of the medication.

Special consideration is applied to administering Indometacin in the elderly, where the lowest dose and frequency are recommended due to a higher potential for adverse events.

Recent Clinical Evidence

Research evidence / Overview of Studies for Indosin

This overview summarizes research evidence, primarily from regulatory sources and peer-reviewed studies, for Indosin (Indometacin), focusing on what researchers have studied, the types of patient groups monitored, and the specific outcomes measured in clinical trials. This context is intended to help understand the research landscape but is not a substitute for medical guidance.

Evidence for Managing Chronic Inflammatory Joint Diseases

The research exploring Indometacin in chronic inflammatory conditions, such as Rheumatoid Arthritis, Ankylosing Spondylitis, and Osteoarthritis, relies on both short-term controlled studies and longer-term observational data. These studies were applied in research contexts involving fluctuating or unstable symptoms. Researchers monitored outcomes related to physical discomfort, like joint pain and stiffness, and functional imbalance, such as walking ability and grip strength.

Short-term Randomized Controlled Trials (RCTs), often last for periods up to a few weeks, were used in research exploring how symptoms change over time. Findings describe patterns observed in these studies, which often relate to changes measured in pain and tenderness. Research indicates that the evidence for these short-term symptomatic changes is well documented.

However, research notes that these studies focus on the management of symptoms rather than the underlying progressive nature of the disease itself. Long-term outcomes and the extended pattern of changes measured are not as well characterized in controlled trials. Most long-term evidence is derived from observational settings, where patterns of daily-life functioning are evaluated over extended periods.

Research on Acute Inflammatory and Painful Conditions

Research also explored Indosin in acute conditions characterized by episodic or disruptive episodes, such as attacks of Acute Gouty Arthritis and localized inflammation like Bursitis or Tendinitis. Findings describe patterns of symptom evolution measured during the acute phase. The evidence base for this acute application is generally well documented. Uncertainty remains because the research is strictly limited to the acute phase of treatment and provides limited information regarding the prevention of future episodes or long-term disease control.

Studies for Specific High-Risk and Niche Applications

Indosin has been evaluated in specialized research settings for specific high-risk and niche medical needs, notably for closing the Patent Ductus Arteriosus (PDA) in premature infants and for the Prevention of Post-ERCP Pancreatitis (PEP). For PDA, studies monitored physiological strain, measuring the rate of ductal closure compared to placebo groups. For PEP, research explored measurements of the incidence rate of the pancreatitis. The evidence base for these specialized uses is highly specific, and long-term follow-up data are not fully established for the neonatal population.

Research Gaps and What Remains Uncertain

Research shows that the findings describe group patterns, and research does not determine whether an individual will respond similarly. For instance, comparative evidence is limited in some areas regarding other available treatment options. Data for certain groups, such as children and individuals with specific co-existing medical conditions, remain insufficient or limited in the main body of evidence. Furthermore, while short-term changes are often well-documented, there is limited information for long-term outcomes and the maintenance of functional improvements over many years.

Key Studies & References

Indomethacin capsules official prescribing information (FDA DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Indosin (FAQ)

Q: How quickly do people usually start to feel the effects of Indosin?

Studies referenced in official product information, particularly for acute gouty arthritis, indicate that definite relief of pain has been reported within 2 to 4 hours after taking a dose. Individual response times may vary.

Q: Is Indosin generally safe to use for a long period of time?

According to official regulatory warnings, the risk of serious cardiovascular events (like heart attack or stroke) and serious gastrointestinal events (like bleeding or ulcers) may increase with the duration of use. The official information reflects a regulatory principle of using the medication for the shortest duration consistent with treatment goals.

Q: Can people with kidney problems use Indosin?

Regulatory labeling advises avoiding the use of Indosin in patients who have advanced kidney disease, unless a healthcare provider determines that the potential benefits clearly outweigh the risk. This caution relates to the possibility that the medication may worsen kidney function.

Q: How long does Indosin stay in your system after you stop taking it?

Official clinical pharmacology information indicates that the mean half-life of indometacin in the plasma is estimated to be about 4.5 hours. The body eliminates the drug through metabolism (breaking it down) and through renal and biliary excretion.

Q: Can Indosin be taken with antacids?

Oral dosage forms are typically directed to be taken with food, immediately after a meal, or with antacids. This is noted in administration instructions as a way to manage potential stomach irritation.

Q: Does Indosin affect blood pressure?

Official documents state that taking indometacin can lead to the onset of new high blood pressure (hypertension) or the worsening of blood pressure that is already high. The potential for this effect is why blood pressure monitoring may be discussed with a qualified professional.

Q: Do studies suggest a need for a dose adjustment over time with Indosin?

Official dosing instructions generally advise that once the acute phase of a condition is controlled, an attempt should be made to reduce the daily dose. The goal of this process is to determine the smallest effective dose needed for ongoing symptom management.

Q: Are there any special instructions for storing Indosin?

Official instructions specify that Indosin must be stored at controlled room temperature, typically 20 C to 25 C. To protect the medicine, it must be kept in its original container, tightly closed, and protected from excessive light, heat, and moisture.

Q: Can Indosin be taken by people over the age of 65?

Regulatory labeling advises that indometacin should be used with greater care in older adults, generally defined as those over 65. The lowest dose and frequency are recommended for this population due to a higher potential for certain adverse events.

Q: Does Indosin interact with common over-the-counter pain relievers?

Official regulatory labeling advises against co-administration with analgesic doses of Aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs). This caution is due to a documented increase in the risk of severe gastrointestinal issues when these medicines are taken together.

Q: Is it true that Indosin can affect my liver function?

Official information notes that severe hepatic reactions (liver damage) have been reported in association with the use of indometacin. Patients are generally advised to discontinue the drug if abnormal liver function tests persist or worsen.

Q: What is Indosin used for besides the main condition?

In addition to conditions like moderate to severe rheumatoid arthritis, approved uses include ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis. It has also been evaluated in specific settings for the closure of patent ductus arteriosus in premature infants.

Q: Can Indosin cause sleep issues, like insomnia or drowsiness?

Yes, according to the official adverse reaction list, both somnolence (drowsiness) and insomnia (difficulty sleeping) are included in the Central Nervous System category. Patients should be aware of these possibilities.

Q: Is it okay to drive while taking Indosin?

Official patient information notes that the medication may cause side effects like drowsiness or dizziness. Official information suggests that caution is appropriate for activities requiring full alertness, such as driving or operating machinery.

Q: Can Indosin be used by children?

The official regulatory documents state that the safety and efficacy of the oral and rectal forms of Indosin are not established for use in children under 14 years of age.

Q: Does Indosin cause weight gain or loss?

The official adverse reaction list includes weight gain and fluid retention in the Metabolic category. This means that weight gain is a reported effect associated with the use of the drug.

Q: Does Indosin affect mood or mental state?

Official adverse reaction reports include various psychiatric disturbances, such as depression, anxiety, mental confusion, and psychic disturbances (including psychotic episodes). These effects are categorized within the Central Nervous System adverse reactions.

Q: Why do official materials sometimes mention Indosin and the heart?

Official documents contain a Boxed Warning that describes the risk of serious cardiovascular thrombotic events, which include myocardial infarction (heart attack) and stroke. This risk is the central focus of the regulatory warning regarding heart health.

Q: Can Indosin cause sensitivity to sunlight?

Some sources linked to regulatory information mention photosensitivity (increased sensitivity to sunlight) as a possible side effect. The official label also reports serious skin reactions which may be related to sun exposure.

Q: What happens if I accidentally take more Indosin than prescribed?

Symptoms reported in regulatory-linked sources in cases of accidental overdose may include nausea, vomiting, severe headache, dizziness, and mental confusion. In severe cases, seizures have also been reported.

Q: How does the body break down Indosin (metabolism)?

Official clinical pharmacology information explains that the body eliminates indometacin via breakdown (metabolism), renal excretion, and biliary excretion. It is metabolized into several primary unconjugated byproducts.

Q: Is Indosin known to cause allergic reactions?

Official labeling notes the potential for severe, life-threatening allergic reactions, known as Anaphylactic Reactions. The drug is also contraindicated (should not be used) in patients with a history of allergic-type reactions after taking aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Q: How is the safety profile of Indosin described in regulatory documents?

The official safety profile is described with a Boxed Warning regarding the risk of serious, potentially fatal Cardiovascular (CV) Thrombotic Events and serious Gastrointestinal (GI) Adverse Events, such as bleeding, ulceration, and perforation.

Q: What should I do if a side effect of Indosin seems unusual or unexpected?

Official regulatory text states that patients should report suspected adverse reactions to their healthcare provider. It also advises reporting through regulatory channels, such as the FDA’s MedWatch program in the United States.

How should Indosin be stored and disposed of?

How to Store and Dispose of Indosin? (Official Regulatory Information)

Storage Component	Official Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not expose the product to freezing or excessive heat.
Protection	Keep the medication in its original container, tightly closed, and protect it from light, heat, and moisture.
Handling (IV)	Reconstituted IV solution is for immediate use; discard any unused portion after preparation.
Child Safety	Keep out of the sight and reach of children at all times.
Disposal Rules	Do not keep outdated or unused medicine. Consult a healthcare professional or pharmacist for instructions on how to properly dispose of the product, as it must be managed according to local pharmaceutical waste regulations.

Indosin